MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm, to co-develop AI-driven antibody drug conjugate (ADC) and anti-aging therapy platforms. This alliance combines Henlius’s comprehensive biopharmaceutical platform, specialized in antibody and Linker Payload technologies, with MindRank’s pioneering applications of AI in pharmaceuticals.
The joint venture aims to establish an AI-powered ADC drug discovery platform designed to expedite the evolution of a new class of ADC drugs, boasting enhanced and differentiated clinical benefits. Furthermore, the collaboration will tap into MindRank’s proprietary biopharmaceutical AI large language models and extensive data analytics to forge an innovative AI anti-aging therapy platform, marking a significant step towards personalized and precision medicine.- Flcube.com
